Nencki Institute of Experimental Biology

Nencki Institute of Experimental Biology
Polish Innovative Neuromedicine Platform "InnoNeuroMed"
2015-03-18
On 17th March, 2015 representatives of major
research institutions and pharmaceutical companies
signed an agreement at the Nencki Institute for the
creation of the first Polish Innovative Neuromedicine
Platform "InnoNeuroMed" The agreement increases
the chances of obtaining EU funds for the
implementation of projects related to the development
neuromedicine, the development of new drugs and
diagnostic methods.
Polish Innovative Neuromedicine Platform
"InnoNeuroMed"is the first of its kind in our country of
a Technological Platform connecting scientists and
entrepreneurs in the field of neuromedicine,
neurobiology and pharmacy. The initiators of its formation are prof. Leszek Kaczmarek, head
of the Laboratory of Molecular Neurobiology of the Nencki Institute, prof. Adam Szewczyk,
director of the Institute, and Dr. Maciej Wieczorek, Chairman of the Board of Celon Pharma
SA. The newly formed initiative aims to increase the importance of modern neuromedicine
within the European economy.
Among the founding members of the platform are: the Nencki Institute of the Experimental
Biology PAS in Warsaw, Institute of Pharmacology PAS in Kraków, Mossakowski medical
Research Centre PAS in Warsaw, Institute of Psychiatry and Neurology in Warsaw,
Pomeranian Medical University in Szczecin, Medical University of Gdansk, Medical University
of Lublin, Medical University of Łódź, Warsaw Medical University, Celon Pharma S.A., ADR
Sp. z. o.o., Genexo Sp. z. o.o., OncoArendi Therapeutics Sp. z. o.o., Polpharma S.A., Selvita
S.A.